| Literature DB >> 34666313 |
Michael B Streiff1, Bjorn Holmstrom2, Dana Angelini3, Aneel Ashrani4, Amro Elshoury5, John Fanikos6, Kleber Yotsumoto Fertrin7, Annemarie E Fogerty8, Shuwei Gao9, Samuel Z Goldhaber6, Krishna Gundabolu10, Ibrahim Ibrahim11, Eric Kraut12, Andrew D Leavitt13, Alfred Lee14, Jason T Lee15, Ming Lim16, Janelle Mann17, Karlyn Martin18, Brandon McMahon19, John Moriarty20, Colleen Morton21, Thomas L Ortel22, Rita Paschal23, Jordan Schaefer24, Sanford Shattil25, Tanya Siddiqi26, Deepak Sudheendra27, Eliot Williams28, Liz Hollinger29, Mai Q Nguyen29.
Abstract
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of patients with cancer who have developed or who are at risk for developing venous thromboembolism (VTE). VTE is a significant concern among cancer patients, who are at heightened risks for developing as well as dying from the disease. The management of patients with cancer with VTE often requires multidisciplinary efforts at treating institutions. The NCCN panel comprises specialists from various fields: cardiology, hematology/hematologic oncology, internal medicine, interventional radiology, medical oncology, pharmacology/pharmacy, and surgery/surgical oncology. This article focuses on VTE prophylaxis for medical and surgical oncology inpatients and outpatients, and discusses risk factors for VTE development, risk assessment tools, as well as management methods, including pharmacological and mechanical prophylactics. Contraindications to therapeutic interventions and special dosing, when required, are also discussed.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34666313 DOI： 10.6004/jnccn.2021.0047
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908